Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing and Optimization of Silybin Phospholipid Complex with Targeted and Immunotherapy
ChiCTR2500099953Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Apr 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of silybin phospholipid complex in Drug-induced hepatitis (DILI) and cancer (4 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Liver biochemical index and Incidence of drug-induced liver injury (DILI). Planned start Apr 2025; status: not yet recruiting.
02
Drugs
silybin phospholipid complex
03
Conditions
Drug-induced hepatitis (DILI)cancer
Beyond the preview
Go deeper on ChiCTR2500099953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099953.